MeSH tree: D27.505.519
A new study led by researchers at The University of Texas MD Anderson Cancer Center has shown that inflammatory arthritis occurring as a side effect of immune checkpoint inhibitors behaves like an immune-memory disease, suggesting ...
6 hours ago
0
2
Researchers at Baylor College of Medicine have developed a drug called CS18 that disrupts cancer cells' ability to survive therapy. The findings, published in Science Advances, support exploring the possibility of using CS18 ...
Aug 5, 2026
0
56
New research by UCLA Health has found GLP-1 medications may reduce the risk of serious fractures for adults with type 2 diabetes.
Aug 4, 2026
0
3
Scientists have long sought to understand why some people with no known risk factors develop cancer while others with significant risk never do. The answer may lie in immune proteins known as autoantibodies (auto-Abs), suggests ...
Jul 25, 2026
0
49
A major pillar of cancer immunotherapy involves stimulating T cells, the specialized killers of the immune system, to attack tumors. But this strategy has been undermined by the tendency of T cells to tire out before finishing ...
Jul 23, 2026
0
107
For patients with rheumatoid arthritis (RA), the timing of Janus kinase (JAK) inhibitor initiation relative to administration of recombinant zoster vaccine (RZV) can affect early response and arthritis control, according ...
Jul 21, 2026
0
4
Viagra was originally developed to treat high blood pressure and chest pain caused by reduced blood flow to the heart, but over the past three decades it has become the world's best-known therapy for erectile dysfunction. ...
Jul 21, 2026
0
86
Significant advances have been made in the development of patient-derived tumor "organoids" for preclinical research in two new studies led by Weill Cornell Medicine investigators. Organoids are three-dimensional clumps of ...
Jul 20, 2026
0
4
More than half of U.S. adults ages 30 to 79—about 87.5 million people—are now recommended for statins to prevent cardiovascular disease under newly updated clinical guidelines, according to a study by University of Pittsburgh ...
Jul 20, 2026
0
11
Wistar scientists have developed a new type of bispecific T cell engager, or BTE, that is effective against ovarian cancer in preclinical studies. It's a major development for this type of immunotherapy, which has been used ...
Jul 19, 2026
0
11
